← Eichor
Study identifier: NCT06959121 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

Condition: Atrial Fibrillation · Maze Procedure  ·  Sponsor: Pulse Biosciences, Inc.

PhaseNA
Planned participants135
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.

This description comes directly from the study's public registry record.

Talk to the study team

Shweta Kalpa, MD  ·  (800) 543-3695  ·  Shweta.Kalpa@pulsebiosciences.com

William A. Knape  ·  (919) 757-2033  ·  bknape@pulsebiosciences.com

Always discuss trial participation with your own doctor first.

Locations (2)

Adventist Heart Institute: Adventist Health St. HelenaSt. Helena, California, United StatesRecruiting
Cardiac Surgery Clinic | Frankel Cardiovascular CenterAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06959121